연구동향 분석

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang Huang Kuo-Hsuan Hsu Chun-Shih Chin Jeng-Sen Tseng Tsung-Ying Yang Kun-Chieh Chen Kang-Yi Su Sung-Liang Yu Jeremy J.W. Chen Gee-Chen Chang 2022년

논문상세정보
인용/피인용
' The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • ErbB receptors
  • adenocarcinoma
  • bevacizumab
  • lung neoplasms
  • tyrosine kinase inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
364 0

0.0%

' The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma' 의 참고문헌

  • Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
    Kris MG [2014]
  • Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
    Ninomiya T [2019]
  • The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base
    Jiao XD [2019]
  • The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma : a multicenter observational study
    Hsu PC [2020]
  • The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  • Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study
    Hochmair MJ [2020]
  • Rare epidermal growth factor receptor(EGFR)mutations in non-small cell lung cancer
    Harrison PT [2020]
  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer(RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial
    Nakagawa K [2019]
  • RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
    Tsai TH [2012]
  • Pretreatment epidermal growth factor receptor(EGFR)T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer
    Su KY [2012]
  • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil
    Reck M [2009]
  • Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer
    Yu HA [2021]
  • Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
    Ko R [2021]
  • Phase 2 study of afatinib alone or combined with bevacizumab in chemonaive patients with advanced non-small-cell lung cancer harboring EGFR mutations : AfaBev-CS study protocol
    Ninomiya T [2019]
  • Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
  • Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers : a systematic review and meta-analysis
    Kuan FC [2015]
  • Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
    Soria JC [2018]
  • Oncology meets immunology : the cancer-immunity cycle
    Chen DS [2013]
  • NEJ026 : final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations
    Maemondo M [2020]
  • Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan
    Hsu KH [2015]
  • Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival
    Lee CK [2017]
  • Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026) : interim analysis of an open-label, randomised, multicentre, phase 3 trial
    Saito H [2019]
  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567) : an open-label, randomised, multicentre, phase 2 study
    Seto T [2014]
  • Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor : West Japan Oncology Group 8715L phase 2 randomized clinical trial
    Akamatsu H [2021]
  • Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial
    Mok TS [2011]
  • Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
    김유진 [2019]
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers : a phase 1/2 single-group open-label trial
    Yu HA [2020]
  • Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer : a phase 2 randomized clinical trial
  • EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer : a propensity score matching analysis
    Tsai JS [2021]
  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, open-label, phase 3 trial
    Wu YL [2017]
  • Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer
    Hong S [2018]
  • CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
    Zhou Q [2019]
  • Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Yu HA [2013]
  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7) : a phase 2B, open-label, randomised controlled trial
    Park K [2016]
  • A real-world analysis of patients with untreated metastatic epidermal growth factor receptor(EGFR)-mutated lung adenocarcinoma receiving first-line erlotinib and bevacizumab combination therapy
    Wang CC [2021]
  • A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER)
    Shi Y [2014]
  • A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations : Okayama Lung Cancer Study Group Trial 1404
    Ninomiya T [2018]
  • A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset : CJLSG1903
    Ito K [2021]